

Toxicology testing using upcyte® hepatocytes

Astrid Nörenberg*, Werner Schroth#, Thomas Mürdter#, Janina Johanning#, Maria Thomas#, Stefan Heinz*

*upcyte technologies GmbH, Osterfeldstr. 12-14, D-22529 Hamburg, Germany

#Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstr. 112, D-70376 Stuttgart, Germany

INTRODUCTION

Summary and novelty: We have developed a technique which causes primary human hepatocytes to proliferate whilst retaining an adult phenotype. The resulting "upcyte® hepatocytes" have the capability to proliferate and express sufficient drug metabolizing activities, a combination which makes them unique. So far 5 different donors of upcyte® hepatocytes have been generated (#10, #740, #151, #653, #422).

Cytotoxicity assay: The cytotoxicity of 31 compounds was measured using ATP and LDH content and MTS metabolism in upcyte® hepatocytes from four donors. The cytotoxicity of the majority of compounds was donor-dependent. Donor 653 was generally less susceptible to cytotoxicity than donors 422A, 151 and 10. There was a good intra- and inter-experimental reproducibility and the predictive capacity of the assay was good such that known non-hepatotoxicants were clearly negative and compounds that were associated with hepatotoxicity caused cytotoxicity in upcyte® hepatocytes.

Micronucleus assay: We optimized the assay conditions incorporating upcyte® hepatocytes into the micronucleus test. A treatment duration of 96 h was optimal for detecting the genotoxicity of the direct-acting, mitomycin C, and the bioactivated compound, cyclophosphamide, whilst negative and "false" positive compounds were correctly identified as negative. The basal MN rate of upcyte® hepatocytes was affected by pre-culture period and medium components. The % MN in control and genotoxicant-treated upcyte® hepatocytes was similar at different growth stages.

Cytotoxicity testing using upcyte® hepatocytes




Figure 1: Morphology of confluent upcyte® hepatocytes showing well-defined cuboidal shape characteristic of primary hepatocytes




Figure 2A: Cytotoxicity of chlorpromazine in upcyte® hepatocytes from different donors (using MTS as the viability measurement)




Figure 2B: Cytotoxicity of tacrine in upcyte® hepatocytes from different donors (using MTS as the viability measurement)




Figure 3: A comparison of the IC₅₀ values generated in upcyte® hepatocytes from donors 422A and 10 with those cited in the literature for primary hepatocytes. Values are from 31 compounds using MTS metabolism.

For cytotoxicity screening, the cells were pre-cultured in 96-well plates as 20 monolayers for 3 days and then treated with test compounds for 4 days. The viability was measured using ATP and LDH content and MTS metabolism in upcyte® hepatocytes from four donors. For some compounds, such as chlorpromazine, the cytotoxicity was similar in upcyte® hepatocytes from different donors (Figure 2A). For other compounds, such as tacrine, the cytotoxicity was donor-dependent e.g. Donor 653 was generally less susceptible to cytotoxicity than donors 151, 422A and 10 (Figure 2B).

There was a good intra- and inter-experimental reproducibility and the predictive capacity of the assay was good such that known non-hepatotoxicants were clearly negative and compounds that were associated with hepatotoxicity caused cytotoxicity in upcyte® hepatocytes. Moreover, there was a good correlation between the MTS IC₅₀ values from our studies with those obtained from the literature for the same compounds in primary human hepatocytes (using MTT), supporting the use of upcyte® hepatocytes as an alternative model to primary cells (Figure 3).

Genotoxicity testing using upcyte® hepatocytes




Figure 4: Effect of treatment and recovery duration on the % MN of cells treated with MMC




Figure 5: Effect of a 96h recovery on the % MN in cells treated with etoposide




Figure 6: Reproducibility of the % MN and cytotoxicity in upcyte® hepatocytes treated with cyclophosphamide

Chemical (CAS number)	Outcome from <i>in vitro</i> MN assay
True positives	
Mitomycin C (MMC) (50-07-7)	Positive in 5 out of 5 experiments
Etoposide (33419-42-0)	Positive in 3 out of 3 experiments
Taxol (33069-62-4)	Positive in 3 out of 3 experiments
Cyclophosphamide (6055-19-2)	Positive in 6 out of 6 experiments
Benzo[a]pyrene (50-32-8)	Positive in 4 out of 4 experiments
True negative chemicals	
Ampicillin trihydrate (7177-48-2)	Negative in 4 out of 4 experiments
Cyclohexanone (108-94-1)	Negative in 5 out of 5 experiments
Melamine (108-78-1)	Negative in 5 out of 5 experiments
Tris(2-ethylhexyl)phosphate (78-42-2)	Negative in 3 out of 3 experiments
False positive chemicals	
2,4-dichlorophenol (120-83-2)	Negative in 3 out of 3 experiments
Benzyl alcohol (100-51-6)	Negative in 4 out of 4 experiments
Curcumin (458-37-7)	Negative in 6 out of 6 experiments
Urea (57-13-6)	Negative in 4 out of 4 experiments
Sulfisoxazole (127-69-5)	Negative in 3 out of 3 experiments
Sodium saccharin (128-44-9)	Negative in 3 out of 3 experiments

Table 1: Outcome of the testing of true positive, true negative and false positive chemicals





Figure 7: Effect of growth stage (PD) on % MN in cells treated with DMSO and MMC

The dotted lines represent the highest and lowest values measured for DMSO (highest = 14.1%, lowest = 3.7%) and MMC (highest = 52.2%, lowest = 23.3%) in upcyte® hepatocytes from Donor 740 at a PD of 25. Values are mean ± SD of triplicate wells in one experiment.

Optimization of treatment and culture conditions for the *in vitro* MN test

Different treatment (8 to 96 h) and recovery durations (0 to 96 h) were tested to determine the optimal conditions for detecting genotoxicants in upcyte® hepatocytes. Longer treatments resulted in higher formation of MN and lower concentrations of test compound were needed to cause the same extent of MN formation (Figure 4). Figure 5 shows that after a 96 h treatment, the cytotoxicity of etoposide was higher when a subsequent recovery period (without test compound) was included. For this reason, a treatment duration of 96 h, without a recovery period was selected as optimal for all compounds. Under these conditions, upcyte® hepatocytes can be incorporated into the *in vitro* MN test to detect both directly acting (e.g. mitomycin C, etoposide (Figure 5)) and metabolically activated genotoxins (e.g. benzo[a]pyrene, cyclophosphamide), whilst true negative and "false" or "misleading" positive compounds were reproducibly and correctly identified as negative (Table 1). The basal MN rate of upcyte® hepatocytes from three other donors was higher than that in Donor 740 (28% compared to -7%, respectively); therefore, the medium was modified by adding oncostatin M and EGF to decrease inherent MN formation (data not shown). There was a very good reproducibility between experiments with respect to the % MN formed and the cytotoxicity in upcyte hepatocytes (Figure 6). The %MN in control (DMSO) and genotoxicant-treated upcyte® hepatocytes was similar at different growth stages and were within the inter-experimental variation values measured for cells at a population doubling (PD) of 24 (Figure 7)

CONCLUSION

In conclusion, these data support the use of upcyte® hepatocytes in the MN test, especially since these cells combine proliferation with a metabolic capacity- thus negating the need for an exogenous bioactivation system. Our data also show that upcyte® hepatocytes can be used as a suitable alternative to primary human hepatocytes for hepatotoxicity screening- combining predictivity and reproducibility with a substantial cell source